In the last three months, 6 analysts have published ratings on Stericycle (NASDAQ:SRCL), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 2 | 4 | 0 | 0 |
| Last 30D | 0 | 1 | 2 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Stericycle, revealing an average target of $73.33, a high estimate of $142.00, and a low estimate of $50.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.7%.
Understanding Analyst Ratings: A Comprehensive Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive Stericycle. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jade Rahmani | Keefe, Bruyette & Woods | Raises | Outperform | $142.00 | $135.00 |
| Sean Dodge | RBC Capital | Lowers | Sector Perform | $62.00 | $69.00 |
| Tobey Sommer | Truist Securities | Raises | Hold | $62.00 | $50.00 |
| Tobey Sommer | Truist Securities | Lowers | Hold | $50.00 | $57.00 |
| David Manthey | Baird | Lowers | Neutral | $55.00 | $62.00 |
| Sean Dodge | RBC Capital | Maintains | Outperform | $69.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Stericycle. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Stericycle compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Stericycle's stock. This examination reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Stericycle's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Stericycle analyst ratings.
Delving into Stericycle's Background
Stericycle is the largest provider of medical waste disposal and data destruction (primarily paper shredding) services in the United States. Its next-closest national competitor in medical waste disposal is Sharps Compliance, which generated $76 million of sales in fiscal 2021 before its 2022 acquisition (about 4% of Stericycle's global regulated waste and compliance revenue). Stericycle's data destruction business, Shred-It, is about twice the size of its closest competitor (Iron Mountain's information destruction segment). Stericycle has a global presence, with about 20% of its revenue earned outside North America.
Stericycle: A Financial Overview
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Stericycle's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -2.83%. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Stericycle's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.97% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.52%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Stericycle's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.24%, the company showcases efficient use of assets and strong financial health.
Debt Management: Stericycle's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.77.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.